Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Depreciation: 2012-2016

  • Agios Pharmaceuticals' Accumulated Depreciation rose 74.48% to $13.4 million in Q4 2016 from the same period last year, while for Dec 2016 it was $13.4 million, marking a year-over-year increase of 74.48%. This contributed to the annual value of $13.4 million for FY2016, which is 74.48% up from last year.
  • According to the latest figures from Q4 2016, Agios Pharmaceuticals' Accumulated Depreciation is $13.4 million, which was up 74.48% from $7.7 million recorded in Q4 2015.
  • Agios Pharmaceuticals' Accumulated Depreciation's 5-year high stood at $13.4 million during Q4 2016, with a 5-year trough of $2.8 million in Q4 2012.
  • Its 3-year average for Accumulated Depreciation is $8.9 million, with a median of $7.7 million in 2015.
  • Data for Agios Pharmaceuticals' Accumulated Depreciation shows a peak YoY skyrocketed of 74.48% (in 2016) over the last 5 years.
  • Over the past 5 years, Agios Pharmaceuticals' Accumulated Depreciation (Quarterly) stood at $2.8 million in 2012, then surged by 52.34% to $4.2 million in 2013, then surged by 32.62% to $5.6 million in 2014, then skyrocketed by 37.89% to $7.7 million in 2015, then skyrocketed by 74.48% to $13.4 million in 2016.
  • Its Accumulated Depreciation stands at $13.4 million for Q4 2016, versus $7.7 million for Q4 2015 and $5.6 million for Q4 2014.